Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: milnacipran hydrochloride Clear all
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 2, 2026, 12:03 AM EDT
Terminated Phase 2 Interventional Results available

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

NCT01471379
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Spencer Dorn, MD, MPH
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Not applicable Interventional Results available

Novel Medication as a Potential Smoking Cessation Aid

NCT02265367
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Levomilnacipran, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 4 Interventional Results available

Effect of Milnacipran on Pain in Fibromyalgia

NCT01288807
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipram
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 2, 2026, 12:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome

NCT02687165
View directory record Official record
Conditions
Post Treatment Lyme Syndrome (PTLS), Chronic Pain
Interventions
Milnacipran and D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 4 Interventional Results available

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Milnacipran
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Savella in Treatment for Provoked Vestibulodynia

NCT01304589
View directory record Official record
Conditions
Vestibulodynia, Vulvodynia
Interventions
Milnacipran
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00314249
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran 100mg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Fresno, California • Pismo Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 2, 2026, 12:03 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

NCT00793520
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2010 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran hydrochloride
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia

NCT00797797
View directory record Official record
Conditions
Fibromyalgia
Interventions
No Treatment Added, Milnacipran Added
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 2, 2026, 12:03 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01331109
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

NCT02288325
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969709
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 2, 2026, 12:03 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

NCT01173055
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 2, 2026, 12:03 AM EDT
Not listed Phase 4 Interventional

Preventive Treatment of Episodic and Chronic Migraine

NCT01319825
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
milnacipran
Drug
Lead sponsor
California Medical Clinic for Headache
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Oct 2, 2026, 12:03 AM EDT
Withdrawn Phase 3 Interventional

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

NCT01221740
View directory record Official record
Conditions
Back Pain
Interventions
Savella
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 2, 2026, 12:03 AM EDT